Iridex Corporation, a leader in laser-based medical systems for eye diseases, will announce its third quarter 2026 financial results on November 17, 2026, after market close. The company will host a conference call to discuss the results and provide a business update. Iridex's products, including its MicroPulse technology, are used globally to treat glaucoma and retinal diseases. Investors can access the call via phone or webcast on the company's website.
Iridex Corporation's upcoming Q3 2026 financial results provide context for healthcare sector activity on Pluang. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: Out of 150 priced US health-sector stocks, 92 rose and 55 fell today. Notable movers include GeneDx Holdings Corp (WGS) at USD 68.89 with a 7.49% increase and a typical hold time of 21 days, Summit Therapeutics Inc (SMMT) at USD 15.86 up 7.09% with 100% buy order activity, and Tango Therapeutics Inc. (TNGX) at USD 23.17 rising 6.48% with a typical hold time of 4 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
